AID Life Science Holdings Limited provides Group earnings guidance for the three months ended March 31, 2020. For the period, the company expected to record a 30% to 40% decrease in loss for the three months ended 31 March 2020 as compared to that for the three months ended 31 March 2019. The decrease in loss was mainly attributable to decrease in research and development costs and amortisation of intangible assets after the disposal of GeneSort.